Resveratrol effects in bladder cancer: A mini review

Abstract

Bladder cancer has a high incidence worldwide and is the most common genitourinary cancer. The treatment of bladder cancer involves surgery and chemotherapy; however high failure rates and toxicity are observed. In this context, the search of new drugs aiming a more effective treatment is extremely necessary. Natural products are an important source of compounds with antiproliferative effects. Resveratrol is a naturally occurring plant polyphenol whose anticancer activity has been demonstrated in different types of cancer. This review summarizes the in vitro and in vivo studies using models of bladder cancer treated with resveratrol and discusses its different mechanisms of action.

Keywords
Apoptosis; bladder cancer; cell cycle arrest; cell signalling; resveratrol

Introduction

Bladder cancer is the most common tumor of the urinary system (Siegel et al., 2018), with approximately 550,000 new cases every year (Richters et al., 2019). Although the highest incidence rates occur in North America, Europe and parts of Western Asia, the mortality rates are greater on developing areas (Dy et al., 2017). The diagnosis occurs predominantly after the age of 55 and the detection of bladder cancer in children and young adults is rare (Saginala et al., 2020). Tobacco and occupational exposure to aromatic amines and polyaromatic hydrocarbons are the main risk factors (Cumberbatch et al., 2018).

Transitional cell carcinoma, also called urothelial carcinoma, is the most common histological type and comprises more than 90% of bladder cancers. Other cell types include squamous cell carcinoma, adenocarcinoma and small-cell carcinoma (Hoskin and Dubash, 2012).

Superficial bladder cancers, confined to the bladder mucosa or submucosal layer, are managed with resection and intravesical therapy. In contrast, muscle invasive bladder cancers are treated with more aggressive procedures, as partial or total cystectomy, with or without chemotherapy (Sanli et al., 2017). Unfortunately, therapeutic failure can occur as lack of drug efficacy, occurrence of serious adverse effects or tumoral progression and recurrence. For example, approximately half of the patients with superficial bladder cancer fail to respond to intravesical bacillus Calmette-Guérin treatment and have a greater chance to progress to muscle invasive disease or present recurrence (Shiota et al., 2020). In the chemotherapy before radical cystectomy, approximately half of the patients do not respond to cisplatin-based chemotherapy and can be affected by toxic side effects (Funt and Rosenberg, 2017).

Although the use of traditional medicine is less frequent (Oyebode et al., 2016), the search of new drugs from natural sources is still of great importance. From 1940 to 2014, approximately 49% of molecules approved to cancer chemotherapy are derived from natural products (Newman and Cragg, 2016).

Resveratrol (RSV) is a polyphenolic compound found in grapes, blackberries, blueberries, raspberries and peanuts. A widely known source of resveratrol is red wine, which contain resveratrol concentrations from 1.9-14.3 mg/L, depending on grape variety, cultivation place and preparation method (Stephan et al., 2017). However, the dominant natural source of RSV is Polygonum cuspidatum, which is extensively used in traditional Chinese and Japanese medicine (Liu et al., 2019). P. cuspidatum leaves present 1000 µg/g of RSV (Liu et al., 2019). Li X et al. (2006) observed extremely high extractable amounts of RSV in berry skins [>100 µg/g of skin fresh weight (FW)] and seeds (>20 µg/g of seed FW) in two rootstock cultivars obtained from hybrids of V. monticula × V. riparia. The authors also showed red-berry cultivars had significantly higher amounts of extractable RSV in skin and seeds (0.66-1.44 µg/g of skin FW and 1.34-1.40 µg/g of seed FW) than green-berry cultivars (0.44-0.73 µg/g of skin FW and 1.22-1.23 µg/g of seed FW). Moreover, the RSV concentration in peanuts is about 1.9 µg/g (Sales and Resurreccion, 2014).

RSV presents numerous biological activities, such as cardioprotective (Wu and Hsieh, 2011), antioxidant (Carrizzo et al., 2013), anti-inflammatory (de Sá Coutinho et al., 2018), antibacterial and antifungal (Vestergaard and Ingmer, 2019), anti-aging (Li Y et al., 2018), neuroprotective (Bastianetto et al., 2015), and others. Jang et al. (1997) were the first to demonstrate the antitumor properties of RSV on the three stages of the carcinogenesis process. Over the years, RSV effects on different types of cancer have been demonstrated and several reviews have been published about these findings (Sinha et al., 2016; Yousef et al., 2017; De Amicis et al., 2019; Huang et al., 2019). Moreover, the selectivity of resveratrol for tumor cells compared to normal cells (immortalized SV-HUC-1 normal human urothelial cells) has already been demonstrated (Zhou et al., 2014). Here, we focus on summarizing the in vitro and in vivo studies that used RSV on bladder cancer models. To the best of our knowledge, this is the first review that summarizes studies about RSV and bladder cancer and emphasizes the mechanisms of action involved in the antiproliferative response in this type of tumor.

In vitro studies about resveratrol effects on bladder cancer

The studies associating the effects of RSV and bladder cancer cells are summarized in Table 1 and Figure 1. Bai et al. (2010) conducted the first study showing the RSV effects in bladder cancer. The authors found that RSV caused G1 cell cycle arrest in T24 cells (transitional cell carcinoma), which was also found later by other authors in T24 and EJ cells (transitional cell carcinoma) (Yang et al., 2017). Bai et al. (2010) showed that the cell cycle arrest occurred through p21 and p38 activation. The increase of p21 and p38 expression inhibited Cyclin D1-CDK4 complex, an important mediator of G1-S transition that acts inhibiting Rb phosphorylation (Donjerkovic and Scott, 2000; Thornton and Rincon, 2009). The cell cycle arrest in T24 cells was accompanied by apoptosis through p-Akt inhibition. Akt signalling pathway is constitutively active in several types of human cancers, including bladder cancer (Sathe and Nawroth, 2018), and contribute to cancer progression, promoting cell proliferation and apoptosis suppression (Nitulescu et al., 2018). Decrease of p-Akt in T24 cells caused apoptosis through the mitochondrial pathways since there was modulation in Bcl-2 family proteins.

Table 1 -
Effects of resveratrol in bladder cancer: in vitro studies.

Cancer cell	Concentration/time	Findings	Mechanisms	Reference
T24	50, 100, 150, 200, 250, 300 µM for 12, 24 or 48 h	Apoptosis Cell cycle arrest at G1 phase	↓p-AKT, ↓Bcl-2, ↓Bcl-xL, ↑Bax, ↓p-Bad, ↑cleaved caspase 3, ↑cleaved PARP ↑p21, ↑p-p38. ↓cyclin D1, ↓CDK4, ↓p-Rb	Bai et al., 2010
BTT739 and T24	12.5, 25, 50, 100 µM for 24 h or 50 µM for 6, 12, 24 or 48 h	Apoptosis	↑ROS production, mitochondrial membrane potential disruption, release of cytocrome c, ↑caspase 9, ↑caspase 3	Lin et al., 2012
ECV304 (derivation from T24)	0.1, 0.5, 1, 2.5, 5, 25, 50, 100 µM for 6 h 30 min or 50 µM for 12, 24 or 48 h	↑cell permeability and ↑DNA fragmentation Apoptosis	↑ROS production ↓Bad/Bcl-2 ratio	Stocco et al., 2012
EJ	100, 150, 200 µM for 1, 1.5 or 2 h in 24 h intervals during 72 h	↓cell growth and cell cycle arrest at S phase Apoptosis	↓STAT3, ↓p-STAT3, ↓p-STAT3 nuclear translocation, ↓c-Myc, ↓cyclin-D1, ↓survivin, ↓VEGF -	Wu et al., 2014
T24 and 5637	10, 30, 50 µM for 48 h.	Apoptosis	↓miR-21, ↓p-Akt, ↓Bcl-2	Zhou et al., 2014
T24	10, 25, 50, 100 µM for 6, 12 or 24 h	↓cell adhesion ↓cell migration and ↓cell invasion	- ↓p-JNK1/2, ↓p-ERK1/2, ↓MMP‑2, ↓MMP‑9	Bai et al., 2017
Pumc‑91/ADM	50, 100, 150, 200, 250, 300, 350 µM for 4, 48 or 72 h,	Sensitized Adriamycin-resistant cells Cell cycle arrest at S phase	↓MRP1, ↓LRP, ↓GST, ↑Topo-II -	Wang et al., 2017
T24 and EJ	20, 40, 60, 80, 100, 150, 200 µM for 6, 12, 24, 48 or 72h	Cell cycle arrest at G1 phase	-	Yang et al., 2017
RT4, 5637 and T24	12.5, 25, 50, 100, 150, 200, 250 µM for 24 h	↓cell proliferation ↓clonogenic survival Morphological changes Cell cycle arrest at phase S (5637 and T24) Apoptosis (RT4) Necrosis (T24) Antiproliferative effects	↑primary DNA damage ↓PLK1 - ↓PLK1 ↓AKT, ↓mTOR, ↓SRC - ↑RASSF1A/↓HOXB3 (T24), ↓DNMT1 (RT4)	Almeida et al., 2019
T24	25, 50, 75, 100, 125, 150, 200 µM for 6, 12, 24, 48 or 72 h	Apoptosis Morphological changes	- -	Yang et al., 2019

Figure 1 -
In vitro effects and mechanism of action of resveratrol. CDK4: cyclin-dependent kinase 4, GST: glutathione S‑transferase, HOXB3: homeobox B3, LRP: lung resistance protein, MMP2: matrix metalloproteinase 2, MMP9: matrix metalloproteinase 9, MRP1: multidrug resistance protein 1, p21: cyclin-dependent kinase inhibitor 1A, p38: p38 mitogen-activated protein kinase, p-ERK1/2: phosphorylated extracellular signal-regulated kinase 1 and 2, p-JNK1/2: phosphorylated c-Jun N-terminal kinase 1 and 2, PLK1: polo like kinase 1, p-Rb: phosphorylated retinoblastoma, RASSF1A: Ras association domain family member 1, ROS: reactive oxygen species, SRC: proto-oncogene tyrosine-protein kinase Src, STAT3: signal transducer and activator of transcription 3, Topo-II: topoisomerase II, VEGF: vascular endothelial growth factor.

Likewise, Lin et al. (2012) found apoptosis through the intrinsic pathway in T24 and BTT739 cell lines (transitional cell carcinoma). RSV treatment caused disruption of mitochondrial membrane potential, which caused release of cytochrome c. In the cytosol, cytochrome c binds to Apaf-1, which recruits and activates caspase-9. This initiator caspase cleaves and activates effector caspases, mainly caspase-3, leading to the cell death (Elmore, 2007). It was also detected in T24 and BTT739 cells increase of reactive oxygen species (ROS) production after RSV treatment. The excessive ROS inside mitochondria might further induce oxidative modification of mitochondrial membrane lipids and change the permeability of the mitochondrial outer membrane, aggravating the disruption of mitochondrial membrane potential (Xu et al., 2010). Yang et al. (2019) also showed apoptosis in T24 cells after RSV treatment, but the authors did not discuss possible mechanisms.

In ECV304 cells (derivative of T24 cell line, transitional cell carcinoma), RSV treatment caused increase of cell permeability and DNA fragmentation, which was associated with ROS production (Stocco et al., 2012). ROS can react easily with nucleic acids, particularly DNA, triggering several structural changes including strand breakage (Bergamini et al., 2004). The study also found apoptosis accompanied by decrease of Bad/Bcl-2 ratio (pro-apoptotic/anti-apoptotic proteins) in ECV304 cells.

In EJ cells (transitional cell carcinoma), cell growth reduction, apoptosis and S phase cell cycle arrest after RSV treatment were accompanied by inhibition of STAT3 signaling pathway and nuclear translocations of Sirt1 and p53 (Wu et al., 2014). STAT3 acts as transcriptional regulator of a variety of tumor-promoting genes such as VEGF, c-MYC, CCND1 (cyclin D1), BIRC5 (survivin), which are involved in tumor development and progression (Santoni et al., 2015). Apoptosis might be associated with Sirt and p53 nuclear translocations. In cancer cells, Sirt1 is associated with cell death/survival and apoptosis by deacetylating of important transcriptional factors, including p53 (Shu et al., 2017).

As mentioned previously, apoptosis caused by resveratrol have been related to Akt pathway (Bai et al., 2010). In T24 e 5637 cells (transitional cell carcinoma), the inhibition of Akt phosphorylation after RSV treatment occurred through inhibition of miR-21 expression (Zhou et al., 2014). Tao et al. (2011) showed the overexpression of miR‑21 promoted the proliferation of bladder cancer cell lines.

Metastasis is the most fatal characteristic of bladder cancer and it is a multistep process that is dependent on cellular activities, including migration and invasion of cancer cells (Steeg, 2006). Bai et al. (2017) focused on establishing the RSV inhibitory effects on these processes in T24 cells and found that the possible mechanism might be suppression of MAPK pathway. RSV treatment decreased JNK1/2 and ERK1/2 phosphorylation, resulting in the inhibition of metalloproteinases MMP‑2 and MMP‑9. Several studies have demonstrated that JNK1/2 and ERK1/2 transcriptionally regulate the expression of MMP‑2 and MMP‑9, which results in regulation of cell migration and invasion (Crowe et al., 2001; Wang et al., 2003; Moon et al 2004).

Wang et al. (2017) demonstrated that RSV treatment was able to reverse drug resistance in Adriamycin‑resistant pumc‑91 cells (Pumc‑91/ADM) (transitional cell carcinoma) through different mechanisms, as decrease of MRP1, LRP, GST and increase of Topo-II expression. All these proteins are important to drug resistance process. MRP1, multidrug resistance protein 1, acts as an efflux pump, which rapidly extrudes numerous anticancer drugs from the cancer cells (Lu et al., 2015). LRP, lung resistance protein, mediates drug resistance by transporting drugs from the nucleus to the cytoplasm through vesicular transport (Scheffer et al., 2000). GST, glutathione S‑transferase, is a phase II detoxification enzyme. However, tumor cells also utilize GST to form a complex between antitumor drugs and glutathione, which is excreted out of the tumor cell by Pgp and MRP (Dong et al., 2018). Topoisomerase II (Topo-II) is a nuclear protein that is usually highly expressed during active cell proliferation, being common its overexpression in tumors. However, it is supposed that decreased expression of Topo II is associated with drug resistance (Tsang et al., 2006; Yu et al., 2014). Several chemotherapeutic agents, as anthracyclines, epipodophy and amsacrine, interfere with DNA replication and promote DNA strand breaks via forming drug‑Topo‑II‑DNA complexes in cancer cells. The downregulation of Topo II may alter the crosslinking and production of DNA complexes, resulting in a decline in chemosensitivity (Zhao et al., 2016).

Almeida et al. (2019) showed that RSV has antiproliferative effects in bladder cancer cells independent of the TP53 gene status (RT4 - TP53 wild type, transitional cell carcinoma, 5637 and T24 - TP53 mutant). TP53 gene is considered the guardian of the genome, because it responds to stress signals inducing cell cycle arrest, apoptosis or DNA repair (Kastenhuber and Lowe, 2017). TP53 mutations are common in muscle-invasive bladder cancer and are correlated with poor prognosis (Solomon and Hansel, 2016). In RT4, 5637 and T24 cells, the reduction of cell proliferation was associated with DNA primary damage caused by RSV treatment. The reduction of colonies formation was accompanied by reduction of PLK1 gene expression after RSV treatment. Synthetic inhibitors of PLK1 caused similar effect in the same cells (Brassesco et al., 2013), showing the importance of this gene for clonogenic survival.

The authors also demonstrated that different mechanisms of action can be activated in TP53 mutated or wild type cells after RSV treatment (Almeida et al., 2019). In TP53 mutated cells (5637 and T24), the decrease of PLK1 expression was also associated with cell cycle arrest at S phase, since its encoded protein is necessary to S phase progress (Shen et al., 2013). In T24 cells, RSV treatment also caused modulation of pathways connected to RASSF1A and HOXB3 genes. RASSF1A is a tumor suppressor gene, whose promoter region hypermethylation causes its inhibition in many cancers, including bladder cancer (Baylin and Herman, 2000). RASSF1A silencing occurs through the HOXB3 oncogene that induces DNMT3B expression, a gene that encodes a DNA methylation enzyme. Overexpression of DNMT3B caused by HOXB3 results in hypermethylation of RASSF1A promoter region (Palakurthy et al., 2009).

In wild type cells (RT4), the apoptosis caused by RSV treatment was accompanied by reduction of AKT/mTOR and SRC gene expression (Almeida et al., 2019). Reduction of the protein encoded by SRC gene causes inhibition of FAK phosphorylation, an anti-apoptotic protein, favouring cell death (Kong et al., 2015). In this cell line, there was also reduction of DNMT1 gene expression, which may be contributing to demethylation of tumor suppressor genes (Almeida et al., 2019).

The activity of RSV loaded in nanoformulation, aiming its use in blader cancer, was investigated only by Almeida et al. (2020). The authors showed that polymeric micelles were able to preserve the cytotoxic activity of free resveratrol in RT4 and T24 cells.

In vivo studies about resveratrol effects in bladder cancer

Currently, there are only two studies about RSV in bladder cancer models (transitional cell carcinoma) in vivo (Table 2 and Figure 2). Bai et al. (2010) used a xenograft model of bladder cancer to investigate RSV effects in vivo. The authors found that RSV treatment significantly slowed the growth of tumors and it was associated with expression decrease of the pro-angiogenic regulators VEGF and FGF-2. Angiogenesis is an important process for tumor growth and progression, being an interest approach to treat cancer (Li T et al., 2018).

Wu et al. (2014) demonstrated that RSV intravesical treatment inhibited tumor growth in the orthotopic model used. The in vivo effect of RSV was associated with inhibition of STAT3 signalling pathway as discussed for its in vitro effects. Interestingly, the authors also showed that RSV treatment did not cause local irritation, indicating its safety for intravesical use. The transitional epithelia of bladder walls were undamaged, without capillary congestion or inflammatory lymphocyte infiltration.

Table 2 -
Effects of resveratrol in bladder cancer: in vivo studies.

Animal model	Dose/duration	Findings	Mechanism	Reference
BALB⁄c-nude mice, male, 4 weeks old, injected subcutaneous with T24 cells into flanks	20 mg⁄ kg once daily for 4 weeks	↓tumor growth	↓VEGF, ↓FGF-2	Bai et al., 2009
BALB/c-nude mice, female, 4 weeks old, injected with EJ cells into sub-epithelial layer urinary bladders	200 µM in two day intervals for 28 days	↓tumor growth Apoptosis	↓STAT3, ↓p-STAT3, ↓c-Myc, ↓cyclinD1, ↓survivin, ↓VEGF -	Wu et al., 2014

Figure 2 -
In vivo effects and mechanism of action of resveratrol. FGF2: fibroblast growth factor 2, STAT3: signal transducer and activator of transcription 3, VEGF: vascular endothelial growth factor.

Studies about resveratrol effects in combination with other compounds in bladder cancer

The studies investigating the effects of RSV combined with other compounds to treat bladder cancer are summarized in Table 3. Alayev et al. (2016) studied the effects of RSV in combination with rapamycin on the inhibition of PI3K/Akt/mTOR signaling pathway. This pathway is related to the regulation of multiple cellular metabolic processes, cell growth, proliferation and survival (Yu and Cui, 2016). Its activation is very common in bladder cancer (Liu et al., 2018). Previous studies showed that rapamycin and everolimus (mTOR inhibitors) were able to inhibit growth of bladder tumor cells and bladder tumor xenograft models (Fechner et al., 2009; Mansure et al., 2009; Chiong et al., 2011). However, the use of mTOR inhibitors in monotherapy is not an interesting strategy. mTOR is involved in a negative feedback loop with PI3K and Akt; when mTOR levels decline, PI3K and Akt levels increase and cross-talk with other growth pathways (Abdelnour-Berchtold et al., 2010). In this context, Alayev et al. (2016) demonstrated that RSV and rapamycin combination was effective since it inhibited the levels of several mTOR downstream effectors (p-56K1, p-S6, p-4EBP1, and p-eIF4B) as well as was able to prevent rapamycin-induced reactivation of Akt. The authors also showed that the combination caused apoptosis, reduced cell migration and clonogenic survival.

One of the options to address multidrug resistance problem is using drug combination (Lou et al., 2018). It has been reported that RSV can reverse multidrug resistance in cancer cells. Moreover, it can sensitize cancer cells to standard chemotherapeutic agents when used in combination with clinically used drugs (Ko et al., 2017). Cho et al. (2019; 2020) studied the effects of RSV to overcome gemcitabine resistance in bladder cancer. The authors showed that the combination of RSV with gemcitabine caused an additive cytotoxic effect in bladder cancer cells T24-GCB (gemcitabine resistant cell line). They investigated modulation in some proteins related to drug resistance in bladder cancer, as ATP binding cassette subfamily C member 2 (ABCC2), deoxycytidine kinase (DCK), thymidine kinase 1 (TK1), and thymidine kinase 2 (TK2). However, RSV may act by other mechanism since those proteins levels did not change as expected.

Table 3 -
Resveratrol effects in combination with other compounds in bladder cancer.

Cancer cell	Concentration/time	Combination	Findings	Mechanisms	Reference
HCV39, 639V and MGH-U1	100 µM for 24 or 48 h	Rapamycin 20 nM	Antiproliferative effects Apoptosis ↓cell migration ↓clonogenic survival	↓p-Akt, ↓p-mTOR, ↓p-56K1, ↓p-S6, ↓p-4EBP1, ↓p-eIF4B ↑cleaved caspase 3, ↑cleaved PARP, ↓survivin, ↓mcl1 - -	Alayev et al., 2016
T24-GCB	75 and150 µM for 72 h	Gemcitabine 10 µM	Sensitized gemcitabine-resistant cells Apoptosis	- ↑cleaved PARP	Cho et al., 2019
T24-GCB	75 and 150 µM for 72 h	Gemcitabine 10 µM	Sensitized gemcitabine-resistant cells	-	Cho et al., 2020

Future perspectives

Clinical trials with healthy volunteers have shown that RSV administration does not cause serious adverse events (Boocock et al., 2007; Almeida et al., 2009; Brown et al., 2010). However, these studies also showed that RSV presents rapid metabolism and low bioavailability, requiring strategies to improve its future use. Some strategies such as optimization of drug delivery with formulations and synergistic or additive interactions with other phytochemicals were reported to increase RVS bioavailability (Amri et al., 2012; Smoliga and Blanchard, 2014; Santos et al., 2019).

Although there are no studies about RSV and bladder cancer in humans, the effects of this compound in other cancers were already investigated in clinical trials. Patel et al. (2010) demonstrated that the treatment with RSV (0.5-1.0 g/day, for 8 days) reduced cell proliferation in colorectal tumor samples from patients. Additionally, the authors reported good tolerability of patients to treatment. Howells et al. (2011) also demonstrated good results in patients with colorectal cancer and liver metastasis. After the treatment with RSV (5 grams/day for 14 days), there was an increase in caspase-3 expression in liver tumor samples. Another study showed that the intake of 5-50 mg, twice daily, for 12 weeks caused a reduction of methylation of the tumor suppressor gene RASSF1A in women at increased risk of breast cancer (Zhu et al., 2012). These clinical findings, the possibility of optimization of drug delivery, few side effects observed and the results of in vivo observations and in vitro experiments discussed above are optimistic and encourage further studies about RSV effects in bladder cancer.

Conclusion

RSV has been found to inhibit cancer cell proliferation, cell migration, and invasion, induce cell cycle arrest, and trigger apoptosis in bladder cancer cells. Besides that, RSV decrease tumor growth in bladder cancer models in vivo. These anticancer effects are related to its ability to modulate several signaling molecules involved in cancer processes. Thus, RSV is a potential agent for treating bladder cancer. Further in vivo studies using the compound alone or in combination with other drugs are needed to confirm the effectiveness of RSV in bladder cancer.

Acknowledgments

This study was supported by Universidade Federal de Ouro Preto(PROPP 23/2019 - grant number 23109.004079/2019-53).

References

• Abdelnour-Berchtold E, Cerantola Y, Roulin D, Dormond-Meuwly A, Demartines N and Dormond O (2010) Rapamycin-mediated FOXO1 inactivation reduces the anticancer efficacy of rapamycin. Anticancer Res 30:799-804.
• Alayev A, Salamon RS, Schwartz NS, Berman AY, Wiener SL and Holz MK (2016) Combination of rapamycin and resveratrol for treatment of bladder cancer. J Cell Physiol 232:436-446.
• Almeida L, Vaz-da-Silva M, Falcão A, Soares E, Costa R, Loureiro AI, Fernandes-Lopes C, Rocha JF, Nunes T, Wright L et al, (2009) Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. Mol Nutr Food Res 53:7-15.
• Almeida TC, Guerra CCC, de Assis BLG, de Oliveira Aguiar Soares RD, Garcia CCM, Lima AA and da Silva GN (2019) Antiproliferative and toxicogenomic effects of resveratrol in bladder cancer cells with different TP53 status. Environ Mol Mutagen 60:740-751.
• Almeida TC, Seibert JB, Almeida SHS, Amparo TR, Teixeira LFM, Barichello JM, Postacchini BB, Santos ODH and da Silva GN (2020) Polymeric micelles containing resveratrol: development, characterization, cytotoxicity on tumor cells and antimicrobial activity. Braz J Pharm Sci 56:e18411.
• Amri A, Chaumeil JC, Sfar S and Charrueau C (2012) Administration of resveratrol: what formulation solutions to bioavailability limitations? J Control Release 158:182-193.
• Bai Y, Mao QQ, Qin J, Zheng XY, Wang YB, Yang K, Shen HF and Xie LP (2010) Resveratrol induces apoptosis and cell cycle arrest of human T24 bladder cancer cells in vitro and inhibits tumor growth in vivo Cancer Sci 101:488-493.
• Bai Y, Yang H, Zhang G, Hu L, Lei Y, Qin Y, Yang Y, Wang Q, Li R and Mao Q (2017) Inhibitory effects of resveratrol on the adhesion, migration and invasion of human bladder cancer cells. Mol Med Rep 15:885-889.
• Bastianetto S, Ménard C and Quirion R (2015) Neuroprotective action of resveratrol. Biochim Biophys Acta 1852:1195-1201.
• Baylin SB and Herman JG (2000) DNA hypermethylation in tumorigenesis: Epigenetics joins genetics. Trends Genet 16:168–174.
• Bergamini CM, Gambetti S, Dondi A and Cervellati C (2004) Oxygen, reactive oxygen species and tissue damage. Curr Pharm Des 10:1611-1626.
• Boocock DJ, Faust GE, Patel KR, Schinas AM, Brown VA, Ducharme MP, Booth TD, Crowell JA, Perloff M, Gescher AJ, et al, (2007) Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev 16:1246-1252.
• Brassesco MS, Pezuk JA, Morales AG, De Oliveira JC, Roberto GM, Da Silva GN, Oliveira HF, Scrideli CA and Tone LG (2013) In vitro targeting of polo-like kinase 1 in bladder carcinoma: Comparative effects of four potent inhibitors. Cancer Biol Ther 14:648-657.
• Brown VA, Patel KR, Viskaduraki M, Crowell JA, Perloff M, Booth TD, Vasilinin G, Sen A, Schinas AM, Piccirilli G et al, (2010) Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis. Cancer Res 70:9003-9011.
• Carrizzo A, Forte M, Damato A, Trimarco V, Salzano F, Bartolo M, Maciag A, Puca AA and Vecchione C (2013) Antioxidant effects of resveratrol in cardiovascular, cerebral and metabolic diseases. Food Chem Toxicol 61:215-226.
• Chiong E, Lee IL, Dadbin A, Sabichi AL, Harris L, Urbauer D, McConkey DJ, Dickstein RJ, Cheng T and Grossman HB (2011) Effects of mTOR inhibitor everolimus (RAD001) on bladder cancer cells. Clin Cancer Res 17:2863-2873.
• Cho CJ, Yang CW, Wu CL, Ho JY, Yu CP, Wu ST and Yu DS (2019) The modulation study of multiple drug resistance in bladder cancer by curcumin and resveratrol. Oncol Lett 18:6869-6876.
• Cho CJ, Yu CP, Wu CL, Ho JY, Yang CW and Yu DS (2020) Decreased drug resistance of bladder cancer using phytochemicals treatment. Kaohsiung J Med Sci:128-135.
• Crowe DL, Tsang KJ and Shemirani B (2001) Jun N‑terminal kinase 1 mediates transcriptional induction of matrix metalloproteinase 9 expression. Neoplasia 3:27‑32.
• Cumberbatch MGK, Jubber I, Black PC, Esperto F, Figueroa JD, Kamat AM, Kiemeney L, Lotan Y, Pang K, Silverman DT et al, (2018) Epidemiology of bladder cancer: A systematic review and contemporary update of risk factors in 2018. Eur Urol 74:784-795.
• De Amicis F, Chimento A, Montalto FI, Casaburi I, Sirianni R and Pezzi V (2019) Steroid receptor signallings as targets for resveratrol actions in breast and prostate cancer. Int J Mol Sci 20:1087.
• de Sá Coutinho D, Pacheco MT, Frozza RL and Bernardi A (2018) Anti-inflammatory effects of resveratrol: Mechanistic insights. Int J Mol Sci 19:1812.
• Dong SC, Sha HH, Xu XY, Hu TM, Lou R, Li H, Wu JZ, Dan C and Feng J (2018) Glutathione S-transferase π: a potential role in antitumor therapy. Drug Des Devel Ther 12:3535-3547.
• Donjerkovic D and Scott DW (2000) Regulation of the G1 phase of the mammalian cell cycle. Cell Research 10:1-16.
• Dy GW, Gore JL, Forouzanfar MH, Naghavi M and Fitzmaurice C (2017) Global burden of urologic cancers, 1990-2013. Eur Urol 71:437-446.
• Elmore S (2007) Apoptosis: a review of programmed cell death. Toxicol Pathol 35:495-516.
• Fechner G, Classen K, Schmidt D, Hauser S and Muller SC (2009) Rapamycin inhibits in vitro growth and release of angiogenetic factors in human bladder cancer. Urology 73:665-668.
• Funt SA and Rosenberg JE (2017) Systemic, perioperative management of muscle-invasive bladder cancer and future horizons. Nat Rev Clin Oncol 14:221-234.
• Hoskin P and Dubash S (2012) Bladder conservation for muscle-invasive bladder cancer. Expert Rev Anticancer Ther 12:1015-1020.
• Howells LM, Berry DP, Elliott PJ, Jacobson EW, Hoffmann E, Hegarty B, Brown K, Steward WP and Gescher AJ (2011) Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases--safety, pharmacokinetics, and pharmacodynamics. Cancer Prev Res 4:1419-1425.
• Huang XT, Li X, Xie ML, Huang Z, Huang YX, Wu GX, Peng ZR, Sun YN, Ming QL, Liu YX et al, (2019) Resveratrol: Review on its discovery, anti-leukemia effects and pharmacokinetics. Chem Biol Interact 306:29-38.
• Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CWW, Fong HHS, Farnsworth NR, Kinghorn AD, Mehta RG et al, (1997) Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275:218-220.
• Kastenhuber ER and Lowe SW (2017) Putting p53 in context. Cell 170:1062-1078.
• Ko JH, Sethi G, Um JY, Shanmugam MK, Arfuso F, Kumar AP, Bishayee A and Ahn KS (2017) The role of resveratrol in cancer therapy. Int J Mol Sci 18:2589.
• Kong D, Chen F and Sima NI (2015) Inhibition of focal adhesion kinase induces apoptosis in bladder cancer cells via Src and the phosphatidylinositol 3-kinase/Akt pathway. Exp Ther Med 10:1725-1731.
• Li T, Kang G, Wang T and Huang H (2018) Tumor angiogenesis and anti-angiogenic gene therapy for cancer. Oncol Lett 16:687-702.
• Li X, Wu B, Wang L and Li S (2006) Extractable amounts of trans-resveratrol in seed and berry skin in Vitis evaluated at the germplasm level. J Agric Food Chem 54:8804-8811.
• Li YR, Li S and Lin CC (2018) Effect of resveratrol and pterostilbene on aging and longevity. Biofactors 44:69-82.
• Lin X, Wu G, Huo WQ, Zhang Y and Jin FS (2012) Resveratrol induces apoptosis associated with mitochondrial dysfunction in bladder carcinoma cells. Int J Urol 19:757-764.
• Liu ST, Hui G, Mathis C, Chamie K, Pantuck AJ and Drakaki A (2018) The current status and future role of the phosphoinositide 3 kinase/AKT signaling pathway in urothelial cancer: an old pathway in the new immunotherapy era. Clin Genitourinary Cancer 16:e269-e276.
• Liu Z, Xu J, Wu X, Wang Y, Lin Y, Wu D, Zhang H and Qin J (2019) Molecular analysis of UV-C induced resveratrol accumulation in Polygonum cuspidatum leaves. Int J Mol Sci 20:6185.
• Lou JS, Yao P and Tsim KWK (2018) Cancer treatment by using traditional Chinese medicine: probing active compounds in anti-multidrug resistance during drug therapy. Curr Med Chem 25:5128-5141.
• Lu JF, Pokharel D and Bebawy M (2015) MRP1 and its role in anticancer drug resistance. Drug Metab Rev 47:406-419.
• Mansure JJ, Nassim R, Chevalier S, Rocha J, Scarlata E and Kassouf W (2009) Inhibition of mammalian target of rapamycin as a therapeutic strategy in the management of bladder cancer. Cancer Biol Ther 8:2339-2347.
• Moon SK, Kim HM, Lee YC and Kim CH (2004) Disialoganglioside (GD3) synthase gene expression suppresses vascular smooth muscle cell responses via the inhibition of ERK1/2 phosphorylation, cell cycle progression, and matrix metalloproteinase‑9 expression. J Biol Chem 279:33063‑33070.
• Newman DJ and Cragg GM (2016) Natural products as sources of new drugs from 1981 to 2014. J Nat Prod 79:629-661.
• Nitulescu GM, Van De Venter M, Nitulescu G, Ungurianu A, Juzenas P, Peng Q, Olaru OT, Grădinaru D, Tsatsakis A, Tsoukalas D, Spandidos DA and Margina D (2018) The Akt pathway in oncology therapy and beyond (Review). Int J Oncol 53:2319-2331.
• Oyebode O, Kandala NB, Chilton PJ and Lilford RJ (2016) Use of traditional medicine in middle-income countries: A WHO-SAGE study. Health Policy Plan 31:984-991.
• Palakurthy RK, Wajapeyee N, Santra MK, Gazin C, Lin L, Gobeil S and Green MR (2009) Epigenetic silencing of the RASSF1A tumor suppressor gene through HOXB3-Mediated induction of DNMT3B expression. Mol Cell 36:219–230.
• Patel KR, Brown VA, Jones DJ, Britton RG, Hemingway D, Miller AS, West KP, Booth TD, Perloff M, Crowell JA et al, (2010) Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. Cancer Res 70:7392-7399.
• Richters A, Aben KKH and Kiemeney LALM (2019) The global burden of urinary bladder cancer: an update. World J Urol 38:1895-1904.
• Saginala K, Barsouk A, Aluru JS, Rawla P, Padala SA and Barsouk A (2020) Epidemiology of bladder cancer. Med Sci (Basel) 8:15.
• Sales JM and Resurreccion AV (2014) Resveratrol in peanuts. Crit Rev Food Sci Nutr 54:734-770.
• Sanli O, Dobruch J, Knowles MA, Burger M, Alemozaffar M, Nielsen ME and Lotan Y (2017) Bladder cancer. Nat Rev Dis Primers 3:17022.
• Santoni M, Conti A, Piva F, Massari F, Ciccarese C, Burattini L, Cheng L, Lopez-Beltran A, Scarpelli M, Santini D et al, (2015) Role of STAT3 pathway in genitourinary tumors. Future Sci OA 1:FSO15.
• Santos AC, Pereira I, Magalhães M, Pereira-Silva M, Caldas M, Ferreira L, Figueiras A, Ribeiro AJ and Veiga F (2019) Targeting cancer via resveratrol-loaded nanoparticles administration: Focusing on in vivo evidence. AAPS J 21:57.
• Sathe A and Nawroth R (2018) Targeting the PI3K/AKT/mTOR pathway in bladder cancer. Methods Mol Biol 1655:335-350.
• Scheffer GL, Schroeijers AB, Izquierdo MA, Wiemer EA and Scheper RJ (2000) Lung resistance‑related protein/major vault protein and vaults in multidrug‑resistant cancer. Curr Opin Oncol 12:550‑556.
• Shen M, Cai Y, Yang Y, Yan X, Liu X and Zhou T (2013) Centrosomal protein FOR20 is essential for S-phase progression by recruiting Plk1 to centrosomes. Cell Res 23:1284-1295.
• Shiota M, Fujimoto N, Yamamoto Y, Takeuchi A, Tatsugami K, Uchiumi T, Matsuyama H and Eto M (2020) Genome-wide association study of genetic variations associated with treatment failure after intravesical Bacillus Calmette-Guérin therapy for non-muscle invasive bladder cancer. Cancer Immunol Immunother 69:1155-1163.
• Shu Y, Ren L, Xie B, Liang Z and Chen J (2017) MiR-204 enhances mitochondrial apoptosis in doxorubicin-treated prostate cancer cells by targeting SIRT1/p53 pathway. Oncotarget 8:97313-97322.
• Siegel RL, Miller KD and Jemal A (2018) Cancer statistics. CA Cancer J Clin 68:7-30.
• Sinha D, Sarkar N, Biswas J and Bishayee A (2016) Resveratrol for breast cancer prevention and therapy: Preclinical evidence and molecular mechanisms. Semin Cancer Biol 40-41:209-232.
• Smoliga JM and Blanchard O (2014) Enhancing the delivery of resveratrol in humans: if low bioavailability is the problem, what is the solution? Molecules 19:17154-17172.
• Solomon JP and Hansel DE (2016) The emerging molecular landscape of urothelial carcinoma. Surg Pathol Clin 9:391-404.
• Steeg PS (2006) Tumor metastasis: Mechanistic insights and clinical challenges. Nat Med 12:895‑904.
• Stephan LS, Almeida ED, Markoski MM, Garavaglia J and Marcadenti A (2017) Red wine, resveratrol and atrial fibrillation. Nutrients 9:1190.
• Stocco B, Toledo K, Salvador M, Paulo M, Koyama N and Toloi MRT (2012) Dose-dependent effect of resveratrol on bladder cancer cells: chemoprevention and oxidative stress. Maturitas 72:72-78.
• Tao J, Lu Q, Wu D, Li P, Xu B, Qing W, Wang M, Zhang Z and Zhang W (2011) microRNA‑21 modulates cell proliferation and sensitivity to doxorubicin in bladder cancer cells. Oncol Rep 25:1721‑1729.
• Thornton TM and Rincon M (2009) Non-classical p38 map kinase functions: cell cycle checkpoints and survival. Int J Biol Sci 5:44-52.
• Tsang WP, Kong SK and Kwok TT (2006) Epidermal growth factor induction of resistance to topoisomerase II toxins in human squamous carcinoma A431 cells. Oncol Rep 16:789-793.
• Vestergaard M and Ingmer H (2019) Antibacterial and antifungal properties of resveratrol. Int J Antimicrob Agents 53:716-723.
• Wang BW, Chang H, Lin S, Kuan P and Shyu KG (2003) Induction of matrix metalloproteinases‑14 and ‑2 by cyclical mechanical stretch is mediated by tumor necrosis factor‑alpha in cultured human umbilical vein endothelial cells. Cardiovasc Res 59:460‑469.
• Wang S, Meng Q, Xie Q and Zhang M (2017) Effect and mechanism of resveratrol on drug resistance in human bladder cancer cells. Mol Med Rep 15:1179-1187.
• Wu JM and Hsieh TC (2011) Resveratrol: a cardioprotective substance. Ann N Y Acad Sci 1215:16-21.
• Wu ML, Li H, Yu LJ, Chen XY, Kong QY, Song X, Shu XH and Liu J (2014) Short-term resveratrol exposure causes in vitro and in vivo growth inhibition and apoptosis of bladder cancer cells. PLoS One 9:e89806.
• Xu SC, He MD, Zhong M, Zhang YW, Wang Y, Yang L, Yang J, Yu Z and Zhou Z (2010) Melatonin protects against Nickel-induced neurotoxicity in vitro by reducing oxidative stress and maintaining mitochondrial function. J Pineal Res 49:86-94
• Yang Y, Li C, Li H, Wu M, Ren C, Zhen Y, Ma X, Diao Y, Ma X, Deng S et al, (2017) Differential sensitivities of bladder cancer cell lines to resveratrol are unrelated to its metabolic profile. Oncotarget 8:40289-40304.
• Yang Y, Zhang G, Li C, Wang S, Zhu M, Wang J, Yue H, Ma X, Zhen Y and Shu X (2019) Metabolic profile and structure-activity relationship of resveratrol and its analogs in human bladder cancer cells. Cancer Manag Res 11:4631-4642.
• Yousef M, Vlachogiannis IA and Tsiani E (2017) Effects of resveratrol against lung cancer: In vitro and in vivo studies. Nutrients 9:1231.
• Yu JS and Cui W (2016) Proliferation, survival and metabolism: the role of PI3K/AKT/mTOR signalling in pluripotency and cell fate determination. Development. 143:3050-3060.
• Yu P, Du Y, Cheng X, Yu Q, Huang L and Dong R (2014) Expression of multidrug resistance-associated proteins and their relation to postoperative individualized chemotherapy in gastric cancer. World J Surg Oncol 12:307.
• Zhao M, Yu S and Zhang M (2016) Differential expression of multidrug resistance‑related proteins in adriamycin‑resistant (pumc‑91/ADM) and parental (pumc‑91) human bladder cancer cell lines. Mol Med Rep 14:4741-4746.
• Zhou C, Ding J and Wu Y (2014) Resveratrol induces apoptosis of bladder cancer cells via miR‑21 regulation of the Akt/Bcl‑2 signaling pathway. Mol Med Rep 9:1467-1473.
• Zhu W, Qin W, Zhang K, Rottinghaus GE, Chen YC, Kliethermes B and Sauter ER (2012) Trans-resveratrol alters mammary promoter hypermethylation in women at increased risk for breast cancer. Nutr Cancer 64:393-400.

Publication Dates

• Publication in this collection
  22 Mar 2021
• Date of issue
  2021

History

• Received
  08 Nov 2020
• Accepted
  01 Feb 2021